|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The HER2 expression in NSCLC was relatively low in the selected Hungarian population; consequently, there is no indication for introduction of trastuzumab for the treatment of lung cancer.
|
16080566 |
2005 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The Lung Cancer Mutation Consortium (LCMC) is a multi-institutional effort to identify and treat oncogenic driver events in patients with lung adenocarcinomas.<b>Experimental Design:</b> Sixteen U.S. institutions enrolled 1,367 patients with lung cancer in LCMC2; 904 were deemed eligible and had at least one of 14 cancer-related genes profiled using validated methods including genotyping, massively parallel sequencing, and IHC.<b>Results:</b> The use of targeted therapies in patients with <i>EGFR, ERBB2,</i> or <i>BRAF</i> p.V600E mutations, <i>ALK, ROS1</i>, or <i>RET</i> rearrangements, or <i>MET</i> amplification was associated with a survival increment of 1.5 years compared with those with such mutations not receiving targeted therapy, and 1.0 year compared with those lacking a targetable driver.
|
29217530 |
2018 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma.
|
26615134 |
2015 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Southern blot analysis of DNA extracted from lung cancer cell lines detected amplification of both the topoisomerase II alpha and ERBB2 genes in the adenocarcinoma line Calu3.
|
1373318 |
1992 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since certain forms of lung cancer are also associated with overexpression of erbB-2, we evaluated the use of this novel therapeutic in this context.
|
8810638 |
1996 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
|
24913497 |
2014 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.
|
18043125 |
2008 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results suggested that the conjugate exhibited selective antiproliferative activity in HER2-overexpressing breast and lung cancer cell lines and was able to block HER2:HER3 heterodimerization.
|
30314880 |
2018 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Regarding HER-2/neu expression (gene or protein level) in lung cancer, several studies with inconsistent results have been recently reported, partially due to variable techniques used and/or heterogeneous populations examined.
|
14639106 |
2003 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
|
17406029 |
2007 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PI3KCA activating mutations were associated with ERBB2 mutations in 12.4% of cases mainly in breast and lung cancer.
|
29941010 |
2018 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
|
18089823 |
2007 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with lung cancer and HER2 mutations developed more brain metastases on treatment than patients with KRAS mutations (28% vs 8%; hazard ratio [HR], 5.2; P < .001) and trended more than patients with EGFR mutations (28% vs 16%; HR, 1.7; P = .06).
|
31469421 |
2019 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Paraffin-embedded sections from 42 cases with lung carcinoma were stained immunohistochemically using the Avidin-Biotin Horseradish Peroxidase method to search for c-erbB-2 reaction.
|
11847606 |
2002 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overlapping with ERBB2-associated human lung cancer genes further identified those ERBB2 downstream players potentially conserved in human and mouse lung tumors.
|
31248101 |
2019 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer.
|
1350198 |
1992 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of the erbB2 receptor occurs in 20-30% of all breast cancers, and seems to be involved in chemotherapeutic resistance of breast cancer cells and radioresistance of lung cancer cells.
|
15586221 |
2005 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that the polymorphisms of the HER-2 gene are associated with an increased susceptibility to lung cancer in females, non-smokers and non-drinkers subgroups in the Korean population.
|
19055823 |
2008 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that a correlation between c-erbB-2 overexpression and tumorigenicity may exist in the Calu3 lung carcinoma cell line.
|
9259403 |
1997 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data suggest that heterodimers of MET with EGFR, HER2, HER3, or RET have differential roles in tumour development, and they provide new insight into the function of trans-phosphorylated RTKs as heterodimerisation partners of MET in lung cancer with MET amplification.
|
21847121 |
2011 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other driver biomarkers in lung cancer (point mutations and rearrangements in specific genes including Her2, BRAF, NUT, MET, ROS1, DDR2, FGFR1, KRAS, and PTEN) might potentially provide additional information for clinical decision making.
|
24420742 |
2014 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.
|
24323026 |
2014 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
No EGFR mutations were detected in BC tissue and no HER2 expression was detected in LC samples.
|
30799393 |
2019 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the ERBB2 receptor have recently been reported in breast cancer at diagnosis and also in gastric, colorectal and lung cancer.
|
22046346 |
2011 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
More recently, erbB2 mutations are found in about 4% of European-derived lung cancer patients.
|
16003726 |
2006 |